AMGXF Quote, Financials, Valuation and Earnings

PeptiDream Inc. has a net margin of -312.66% compared to AnGes, Inc.'s net margin of -25.38%. AnGes, Inc.'s return on equity of -349.76% beat PeptiDream Inc.'s return on equity of -10.42%.

AnGes, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes, Inc. has higher upside potential than PeptiDream Inc., analysts believe AnGes, Inc. is more attractive than PeptiDream Inc..

AnGes, Inc. has a beta of 0.060, which suggesting that the stock is 94.03% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.

AnGes, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes, Inc. pays -- of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.

AnGes, Inc. quarterly revenues are $1.6M, which are smaller than PeptiDream Inc. quarterly revenues of $29.3M. AnGes, Inc.'s net income of -$4.9M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, AnGes, Inc.'s price-to-earnings ratio is -- while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes, Inc. is 21.61x versus 11.79x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma Co., Ltd. has a net margin of -312.66% compared to AnGes, Inc.'s net margin of -24.76%. AnGes, Inc.'s return on equity of -349.76% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.

AnGes, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes, Inc. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe AnGes, Inc. is more attractive than Nxera Pharma Co., Ltd..

AnGes, Inc. has a beta of 0.060, which suggesting that the stock is 94.03% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.

AnGes, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes, Inc. pays -- of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.

AnGes, Inc. quarterly revenues are $1.6M, which are smaller than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. AnGes, Inc.'s net income of -$4.9M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, AnGes, Inc.'s price-to-earnings ratio is -- while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes, Inc. is 21.61x versus 2.34x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Stemcell Holdings, Inc. has a net margin of -312.66% compared to AnGes, Inc.'s net margin of --. AnGes, Inc.'s return on equity of -349.76% beat Stemcell Holdings, Inc.'s return on equity of --.

AnGes, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes, Inc. has higher upside potential than Stemcell Holdings, Inc., analysts believe AnGes, Inc. is more attractive than Stemcell Holdings, Inc..

AnGes, Inc. has a beta of 0.060, which suggesting that the stock is 94.03% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

AnGes, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes, Inc. pays -- of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.

AnGes, Inc. quarterly revenues are $1.6M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. AnGes, Inc.'s net income of -$4.9M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, AnGes, Inc.'s price-to-earnings ratio is -- while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes, Inc. is 21.61x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical Co., Ltd. has a net margin of -312.66% compared to AnGes, Inc.'s net margin of -1.05%. AnGes, Inc.'s return on equity of -349.76% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.

AnGes, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 23.91%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than AnGes, Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than AnGes, Inc..

AnGes, Inc. has a beta of 0.060, which suggesting that the stock is 94.03% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.027, suggesting its less volatile than the S&P 500 by 97.262%.

AnGes, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.65% to investors and pays a quarterly dividend of $0.34 per share. AnGes, Inc. pays -- of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend.

AnGes, Inc. quarterly revenues are $1.6M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. AnGes, Inc.'s net income of -$4.9M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, AnGes, Inc.'s price-to-earnings ratio is -- while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 181.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes, Inc. is 21.61x versus 1.54x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.